Daily obesity tablets are reshaping the race dominated by GLP-1 injections.
The new oral version of Wegovy from Novo Nordisk has seen rapid uptake in the US.
Patients and doctors say pills are easier to use, cheaper and more convenient than weekly shots.
Many users are switching because of insurance costs or needle aversion.
They report steady appetite control and continued weight loss.
Analysts believe tablets will draw in people who avoided injections.
The global obesity-drug market could reach $200bn within the decade.
Rival Eli Lilly is preparing its own pill, orforglipron.
It does not require fasting and may be simpler to take.
More oral and combination treatments are in development.
Injections still produce greater weight loss and will remain important for severe obesity.
Pills are expected to dominate the broader, mildly overweight population.
Falling prices and new insurance coverage in the US will further expand demand.
Rising global obesity rates mean millions of potential new patients.
Researchers say current treatments have reached only a fraction of those eligible.
